AI Article Synopsis
- The EndoBarrier™ is a medical device that mimics gastric bypass surgery to promote weight loss and improve blood sugar levels in individuals with type 2 diabetes.
- A study involving 10 participants with a high body mass index (BMI) and elevated blood sugar levels assessed the device’s effects at various time points: before implantation, 4 weeks after, 36 weeks (before removal), and 24 weeks post-removal.
- Results showed notable weight loss and improved insulin sensitivity shortly after implantation, with some positive effects persisting even 24 weeks after the device was removed, though they lessened over time.
Article Abstract
The EndoBarrier™ medical device is a duodenal-jejunal bypass liner designed to mimic the effects of gastric bypass surgery to induce weight loss and glycaemic improvement. In this study, 10 participants with type 2 diabetes mellitus (T2DM), a mean body mass index (BMI) of 43.3 ± 5.0 (kg/m) and a mean glycated haemoglobin A1c (HbA1c) of 60.6 ± 8.6 mmol/mol were examined at baseline (before implantation of EndoBarrier™), 4 weeks after implantation, at 36 weeks (right before explantation) and 24 weeks after the removal of the device to explore the short and long-term effects on glucose metabolism. Besides a significant reduction in body weight and fat mass, EndoBarrier™ treatment significantly improved insulin sensitivity during Botnia clamp investigations after four weeks of implantation. The beneficial effects decreased over time but remained significant 24 weeks after removal of the device.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070956 | PMC |
| http://dx.doi.org/10.3390/biom11040574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!